Antibody Information

General Information of This Antibody

Antibody ID	ANI0TBOXU
Antibody Name	Bispecific nBT062-natalizumab
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Chimeric IgG4-kappa
Antigen Name	Syndecan-1 (SDC1); Integrin alpha-4 (ITGA4)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

Bispecific nBT062-natalizumab-DM4 [Investigative]

ADC Info

Discovered Using Patient-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 51.60% (Day 56)	Positive CD138 expression (CD138+++/++)
Method Description	Bispecific nBT062-natalizumab-DM4 (4 mg/kg/week for three injections in total) induces efficient tumor cell killing in models of MAXF1322 mammary carcinoma cells with CD138 expression with high expression.
In Vivo Model	Breast cancer PDX model (PDX: MAXF 1322)

Revealed Based on the Cell Line Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.46 nM	Positive CD138 expression (CD138+++/++)
Method Description	WT nBT062-DM4, stable nBT062-DM4, half nBT062-DM4 or bispecific nBT062-natalizumab-DM4 were added to the cells. Cells were incubated and after 5 days the viability was determined using the WST-1 cell proliferation assay.
In Vitro Model	Plasma cell myeloma	NCI-H929 cells		CVCL_1600

References

Ref 1	Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate. PLoS One. 2018 Apr 19;13(4):e0195823. doi: 10.1371/journal.pone.0195823. eCollection 2018.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.